A Digital Art Activity to Enhance Self-Disclosure and the Detection of Psycho-social Distress in Adult Cancer Patients
Launched by M.D. ANDERSON CANCER CENTER · Nov 7, 2023
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a digital art activity can help adult cancer patients express their feelings and experiences related to their illness. The goal is to see if creating art on a digital tablet can make it easier for patients to share their emotional distress and symptoms with their healthcare team. By doing so, the researchers hope to improve the overall care and support these patients receive during treatment.
To participate in this study, candidates need to be at least 18 years old and have been diagnosed with certain types of cancer, such as colorectal, breast, pancreatic, or lung cancer, within the last six months to a year. They must also be currently receiving treatment for their cancer and be able to understand and communicate in English or Spanish. Participants will use digital tablets to create art and share their thoughts and feelings, which may help them connect better with their healthcare providers. It's important to note that patients who have difficulty using digital devices, who are pregnant, or have certain impairments may not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age equal or greater than 18 years
- • 2. Patients who are admitted in the hospital and have received a cancer diagnosis.
- • 3. Suffering from solid cancer or hematological malignancy and receiving active treatment for their cancer.
- • 4. Voluntary written consent.
- • 5. Fluent in English or Spanish.
- Exclusion Criteria:
- • 1. Not being able to use a digital tablet
- • 2. Being speech impaired or vision impaired
- • 3. Patients who are cognitively impaired and unable to read or consent for the study
- • 4. Pregnant women
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Carlos Roldan, MD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported